Uz Stammberger

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ex Vivo Pulmonary Oedema after In Vivo Blast-Induced Rat Lung Injury: Time Dependency, Blast Intensity and Beta-2 Adrenergic Receptor Role.

Ex Vivo Pulmonary Oedema after In Vivo Blast-Induced Rat Lung Injury: Time Dependency, Blast Intensity and Beta-2 Adrenergic Receptor Role.

Journal: Biomedicines

Published: September 01, 2022

Characteristics of inflammatory response and repair after experimental blast lung injury in rats.

Characteristics of inflammatory response and repair after experimental blast lung injury in rats.

Journal: PloS one

Published: April 04, 2022

Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.

Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 06, 2021

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 05, 2020

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 05, 2019

Experience of disease, relationship and sexuality in patients with COPD

Experience of disease, relationship and sexuality in patients with COPD

Journal: Zeitschrift fur Psychosomatische Medizin und Psychotherapie

Published: September 04, 2019

Cytokine-Ion Channel Interactions in Pulmonary Inflammation.

Cytokine-Ion Channel Interactions in Pulmonary Inflammation.

Journal: Frontiers in immunology

Published: August 09, 2017

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Journal: Cancer treatment reviews

Published: April 27, 2017

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: April 12, 2017

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

Journal: American journal of cancer research

Published: March 17, 2017

Outcome of a four-hour smoking cessation counselling workshop for medical students.

Outcome of a four-hour smoking cessation counselling workshop for medical students.

Journal: Tobacco induced diseases

Published: April 05, 2016

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 13, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026